Semper Paratus Acquisition Corporation Warrant (TVGNW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
Semper Paratus Acquisition Corporation Warrant Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| BO Brian Oliveira Clear Street Group Inc. | 282,335 | $15,669.99 | $14,116.75 | -$1,553.24 | -9.91% |
| LV Lindsay Voak Greenland Capital Management LP | 703,029 | $20,739.36 | $35,151.45 | $14,412.09 | 69.49% |
Semper Paratus Acquisition Corporation Warrant (TVGNW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Semper Paratus Acquisition Corporation Warrant ever had a stock split?
Semper Paratus Acquisition Corporation Warrant Profile
| Biotechnology Industry | Healthcare Sector | Ryan H. Saadi CEO | NASDAQ (CM) Exchange | 88165K119 CUSIP |
| US Country | 18 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tevogen Bio Holdings Inc. is a pioneering force in the field of biotechnology, concentrating its efforts on the development of innovative T cell therapeutics tailored for various medical domains such as virology, oncology, and neurology. Situated in Warren, New Jersey, Tevogen stands out as a clinical-stage company that leverages cutting-edge technology to create off-the-shelf precision treatments. These advancements aim to fulfill the critical healthcare gaps faced by patients with acute conditions, including those affected by COVID-19 and its prolonged aftermath, known as long COVID. Through extensive research and development, Tevogen Bio harnesses the power of precision medicine to design therapies that are both impactful and accessible, reflecting their commitment to addressing some of the most pressing medical challenges of our time.
Products and Services
- TVGN 489
This lead investigational precision T cell product by Tevogen Bio Holdings Inc. is at the forefront of the company's innovative approach to combatting COVID-19. Specifically developed for patients at acute risk, TVGN 489 has emerged as a promising therapeutic strategy not only for those currently battling the infection but also for a particular group of individuals grappling with the lingering symptoms of long COVID. The underlying technology and methodology of TVGN 489 embody Tevogen’s commitment to precision healthcare, offering a beacon of hope for patients in need of effective and targeted interventions.
